ASCO GI 2021 | The SMART study: IRE in pancreatic cancer

Shahid Ahmed, PhD, MD, FRCPC, FACP, Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, Canada, describes the rationale and design for the ongoing, prospective Phase II SMART study (NCT04276857) evaluating irreversible electroporation (IRE), a novel non-thermal ablation technology, in locally-advanced pancreatic cancer. The trial in progress, which was presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2021, aims to determine progression-free survival and overall survival rates in patients with locally-advanced pancreatic cancer treated with combination chemotherapy and IRE, as well as identify prognostic and predictive biomarkers and assess quality of life. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).